DELFI liquid biopsy detects liver cancer across diverse international populations, Hopkins-led study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login